14-day Premium Trial Subscription Sign Up For FreeGet Free

Akari Therapeutics Plc Stock Forecast NASDAQ:AKTX

Price Target and Analyst Ratings

Most Recent Rating

B. Riley is very positive about AKTX and gave it a "Buy" rating on August 13, 2020. The price target was set to $5.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2020-08-13 Buy Reiterated by B. Riley $1.86 $5.00

AKTX Stock Trend

The stock lies in the lower part of a wide and weak rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.65 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift.

Given the current short-term trend, the stock is expected to rise 6.96% during the next 3 months and, with a 90% probability hold a price between $1.77 and $2.04 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-30 $1.66 $1.78 $1.91
2021-10-01 $1.66 $1.78 $1.91
2021-10-04 $1.66 $1.79 $1.91
2021-10-05 $1.66 $1.79 $1.91
2021-10-06 $1.66 $1.79 $1.92
2021-10-07 $1.66 $1.79 $1.92
2021-10-08 $1.67 $1.79 $1.92
2021-10-11 $1.67 $1.80 $1.92
2021-10-12 $1.67 $1.80 $1.92
2021-10-13 $1.67 $1.80 $1.93
2021-10-14 $1.67 $1.80 $1.93
2021-10-15 $1.68 $1.80 $1.93
2021-10-18 $1.68 $1.80 $1.93
2021-10-19 $1.68 $1.81 $1.93
2021-10-20 $1.68 $1.81 $1.93
2021-10-21 $1.68 $1.81 $1.94
2021-10-22 $1.69 $1.81 $1.94
2021-10-25 $1.69 $1.81 $1.94
2021-10-26 $1.69 $1.82 $1.94
2021-10-27 $1.69 $1.82 $1.94
2021-10-28 $1.69 $1.82 $1.95
2021-10-29 $1.70 $1.82 $1.95
2021-11-01 $1.70 $1.82 $1.95
2021-11-02 $1.70 $1.83 $1.95
2021-11-03 $1.70 $1.83 $1.95
2021-11-04 $1.70 $1.83 $1.96
2021-11-05 $1.71 $1.83 $1.96
2021-11-08 $1.71 $1.83 $1.96
2021-11-09 $1.71 $1.84 $1.96
2021-11-10 $1.71 $1.84 $1.96

About Akari Therapeutics Plc

Akari Therapeutics Plc Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation C5 complement inhibitor that is in Phase Ib clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and a... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT